Last reviewed · How we verify

Cephalon — Portfolio Competitive Intelligence Brief

Cephalon pipeline: 4 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 3 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Trisenox ARSENIC TRIOXIDE marketed High Risk QT Prolonging Agents Potassium voltage-gated channel subfamily H member 2 Oncology 2000-01-01
Gabitril TIAGABINE marketed Anti-epileptic Agent Sodium- and chloride-dependent GABA transporter 1 Neuroscience 1997-01-01
Gabitril Gabitril marketed Other
Fentanyl Buccal Tablet (FBT) Fentanyl Buccal Tablet (FBT) marketed Opioid analgesic Mu-opioid receptor (MOR) Oncology
CEP-10953 (Armodafinil) CEP-10953 (Armodafinil) phase 3 Wakefulness-promoting agent Dopamine transporter (DAT) Neurology / Sleep Medicine
OraVescent fentanyl (OVF) OraVescent fentanyl (OVF) phase 3 Opioid agonist Mu-opioid receptor (μ-OR) Pain Management
ORAVESCENT Fentanyl Citrate ORAVESCENT Fentanyl Citrate phase 3 Opioid agonist Mu (μ) opioid receptor Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. KK Women's and Children's Hospital · 2 shared drug classes
  2. University Hospital, Ghent · 2 shared drug classes
  3. Janssen Korea, Ltd., Korea · 2 shared drug classes
  4. · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. Alza Corporation, DE, USA · 2 shared drug classes
  7. Ain Shams University · 2 shared drug classes
  8. University of British Columbia · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Cephalon:

Cite this brief

Drug Landscape (2026). Cephalon — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cephalon. Accessed 2026-05-13.

Related